IL290825A - Methods of producing antibody compositions - Google Patents

Methods of producing antibody compositions

Info

Publication number
IL290825A
IL290825A IL290825A IL29082522A IL290825A IL 290825 A IL290825 A IL 290825A IL 290825 A IL290825 A IL 290825A IL 29082522 A IL29082522 A IL 29082522A IL 290825 A IL290825 A IL 290825A
Authority
IL
Israel
Prior art keywords
methods
antibody compositions
producing antibody
producing
compositions
Prior art date
Application number
IL290825A
Other languages
Hebrew (he)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL290825A publication Critical patent/IL290825A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20Probabilistic models
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
IL290825A 2019-09-26 2022-02-23 Methods of producing antibody compositions IL290825A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962906709P 2019-09-26 2019-09-26
PCT/US2020/053090 WO2021062372A1 (en) 2019-09-26 2020-09-28 Methods of producing antibody compositions

Publications (1)

Publication Number Publication Date
IL290825A true IL290825A (en) 2022-04-01

Family

ID=73014594

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290825A IL290825A (en) 2019-09-26 2022-02-23 Methods of producing antibody compositions

Country Status (11)

Country Link
US (1) US20220349898A1 (en)
EP (1) EP4034556A1 (en)
JP (1) JP2022549329A (en)
KR (1) KR20220069982A (en)
CN (1) CN114450593A (en)
AU (1) AU2020355251A1 (en)
BR (1) BR112022005583A2 (en)
CA (1) CA3152547A1 (en)
IL (1) IL290825A (en)
MX (1) MX2022003461A (en)
WO (1) WO2021062372A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308042A (en) * 2021-04-28 2023-12-01 Univ Columbia Antibodies for the treatment and prevention of covid-19 and emerging variants
CA3233279A1 (en) * 2021-10-05 2023-04-13 Amgen, Inc. Fc-gamma receptor ii binding and glycan content

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5714465A (en) 1989-05-19 1998-02-03 Amgen Inc. Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor
US7144731B2 (en) 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US7138500B1 (en) 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US6630143B1 (en) 1993-05-24 2003-10-07 Immunex Corporation Antibodies against flt3 ligand
US7045128B2 (en) 1993-05-24 2006-05-16 Immunex Corporation Antibodies against flt3-ligand
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
AU720232B2 (en) 1996-07-19 2000-05-25 Amgen, Inc. Analogs of cationic proteins
CA2274987C (en) 1996-12-23 2012-01-24 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
US5741772A (en) 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
ATE363533T1 (en) 1997-04-16 2007-06-15 Amgen Inc OSTEOPROTEGERIN BINDING PROTEINS AND RECEPTORS
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999031241A1 (en) 1997-12-17 1999-06-24 Immunex Corporation Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides
EP1042477A1 (en) 1997-12-23 2000-10-11 Immunex Corporation Sigirr dna and polypeptides
WO1999033878A1 (en) 1997-12-25 1999-07-08 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
NZ505499A (en) 1998-01-23 2002-07-26 Immunex Corp Accessory protein-like DNA and polypeptides
ES2353637T3 (en) 1998-08-07 2011-03-03 Immunex Corporation LDCAM MOLECULES.
DE69939982D1 (en) 1998-08-07 2009-01-08 Immunex Corp B7L-1 MOLECULES
PT1129190E (en) 1998-11-13 2007-08-08 Immunex Corp Human tslp dna and polypeptides
EE05627B1 (en) 1998-12-23 2013-02-15 Pfizer Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
JP2001206899A (en) 1999-11-18 2001-07-31 Japan Tobacco Inc HUMAN MONOCLONAL ANTIBODY AGAINST TGF-beta II TYPE RECEPTOR AND MEDICINAL USE THEREOF
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
ES2549767T3 (en) 2000-05-26 2015-11-02 Immunex Corporation Use of interleukin-4 antibodies and compositions thereof
US20050249735A1 (en) 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
AU8881201A (en) 2000-09-05 2002-03-22 Amgen Inc Tnf receptor-like molecules and uses thereof
DK1399483T3 (en) 2001-01-05 2010-08-02 Pfizer Antibodies to insulin-like growth factor receptor I
US6887687B2 (en) 2001-07-30 2005-05-03 Immunex Corporation Nucleic acids encoding human ataxin-1-like polypeptide IMX97018
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
EP1448588A4 (en) 2001-10-23 2006-10-25 Psma Dev Company L L C Psma antibodies and protein multimers
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
AU2002351204B2 (en) 2001-12-03 2008-07-10 Abgenix, Inc. Anti-CD45RB antibodies for use in treating autoimmune disease and transplant rejection
EP1461082A4 (en) 2001-12-03 2006-06-28 Abgenix Inc Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
JP2005516965A (en) 2001-12-28 2005-06-09 アブジェニックス・インコーポレーテッド Method using anti-MUC18 antibody
AU2002361887A1 (en) 2001-12-28 2003-07-24 Abgenix, Inc. Use of antibodies against the muc18 antigen
CA2471849A1 (en) 2001-12-28 2003-07-17 Abgenix, Inc. Antibodies against the muc18 antigen
US7135174B2 (en) 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
PT1527100E (en) 2002-03-29 2009-08-25 Schering Corp Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
MXPA04009681A (en) 2002-04-05 2005-01-11 Amgen Inc Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors.
RU2339647C2 (en) 2002-08-19 2008-11-27 Астразенека Аб Antibodies fighting monocyte chemoattractant protein-1 (mcp-1) and their application
CN100471871C (en) 2002-09-06 2009-03-25 安姆根有限公司 Therapeutic human anti-IL-1R1 monoclonal antibody
US7335743B2 (en) 2002-10-16 2008-02-26 Amgen Inc. Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
KR20120098932A (en) 2003-06-27 2012-09-05 암젠 프레몬트 인코포레이티드 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
GEP20146050B (en) 2003-07-15 2014-03-10 Medarex Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
EP2133362B1 (en) 2003-07-25 2012-04-18 Amgen, Inc Methods relating to LDCAM and CRTAM
HN2004000285A (en) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTIBODIES DIRECTED TO c-MET
EP1659918B1 (en) 2003-08-08 2009-01-14 Amgen Fremont Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
BRPI0416603A (en) 2003-11-07 2007-01-30 Immunex Corp antibody that binds to the human interleukin-4 (il-4) receptor
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
PE20051053A1 (en) 2004-01-09 2005-12-12 Pfizer ANTIBODIES AGAINST MADCAM
JP2007534694A (en) 2004-04-23 2007-11-29 アムジェン インコーポレイテッド Antibody of CD148 angiogenesis-inhibiting domain
CA2561861A1 (en) 2004-04-23 2005-12-15 Amgen Inc. Antibodies to angiogenesis inhibiting domains of cd148
AU2005267722B2 (en) 2004-08-04 2009-10-08 Amgen Inc. Antibodies to Dkk-1
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
ATE492563T1 (en) 2004-11-17 2011-01-15 Amgen Inc COMPLETE HUMAN MONOCLONAL ANTIBODIES AGAINST IL-13
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
WO2006081139A2 (en) 2005-01-26 2006-08-03 Abgenix, Inc. Antibodies against interleukin-1 beta
EP2384767B1 (en) 2005-03-24 2016-03-09 Millennium Pharmaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
EA015534B1 (en) 2005-04-25 2011-08-30 Пфайзер Инк. Antibodies to myostatin and methods of use thereof
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
BRPI0614040B8 (en) 2005-07-18 2021-05-25 Amgen Inc isolated antibody that specifically binds to b7rp1, polypeptide, pharmaceutical composition, expression vector, host cell, isolated cell line, and methods for detecting b7rp1 in a biological sample and producing an antibody or polypeptide
PE20071101A1 (en) 2005-08-31 2007-12-21 Amgen Inc POLYPEPTIDES AND ANTIBODIES
PT2447283E (en) 2005-09-07 2015-10-08 Pfizer Human monoclonal antibodies to activin receptor-like kinase-1 (alk-1)
CA2633956C (en) 2005-12-13 2016-12-06 Olivia Raeber Binding proteins specific for insulin-like growth factors and uses thereof
AR056857A1 (en) 2005-12-30 2007-10-24 U3 Pharma Ag DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
TWI395754B (en) 2006-04-24 2013-05-11 Amgen Inc Humanized c-kit antibody
JP2009537143A (en) 2006-05-19 2009-10-29 アムゲン インコーポレイティッド Antibodies against SARS coronavirus
CL2007002567A1 (en) 2006-09-08 2008-02-01 Amgen Inc ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN.
CL2007002668A1 (en) 2006-09-20 2008-05-09 Amgen Inc ANTIGEN UNION PROTEIN THAT JOINS THE HUMAN GLUCAGON RECEIVER; NUCLEIC ACID THAT CODIFIES IT; METHOD OF PRODUCTION; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT; AND ITS USE TO TREAT OR PREVENT TYPE 2 DIABETES.
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
CL2008000935A1 (en) 2007-04-02 2008-11-07 Amgen Fremont Inc Anti-ige human monoclonal antibody or fragment thereof; nucleic acid encoding it; vector and host cell; Preparation method; pharmaceutical composition that includes it; and its use in the treatment of disorders related to ige.
CL2008001887A1 (en) 2007-06-29 2008-10-03 Amgen Inc PROTEINS OF UNION TO ANTIGEN THAT JOIN THE RECEPTOR ACTIVATED BY PROTEASES 2 (PAR-2); NUCLEIC ACID THAT CODES THEM; VECTOR AND GUEST CELL; METHOD OF PRODUCTION; AND COMPOSITION THAT UNDERSTANDS THEM.
CL2008002153A1 (en) 2007-07-24 2009-06-05 Amgen Inc Isolated antibody or antigen-binding fragment thereof that binds to the yl-18 (yl-18r) receptor; encoding nucleic acid molecule; host cell comprising it; pharmaceutical composition; medical use to treat or prevent a condition associated with il-18r; In vitro method to inhibit the binding of yl-18 to yl-18r.
TWI595005B (en) 2007-08-21 2017-08-11 安健股份有限公司 Human c-fms antigen binding proteins
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
AU2009246946B2 (en) 2008-05-01 2013-09-26 Amgen Inc. Anti-hepcidin antibodies and methods of use
TWI477511B (en) 2009-03-20 2015-03-21 Amgen Inc Alpha4beta7 heterodimer specific antagonist antibody
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
WO2013114164A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
EP2809773B1 (en) 2012-01-30 2020-09-02 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
WO2013114167A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Process of obtaining glycoform composition
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
WO2015128793A1 (en) 2014-02-25 2015-09-03 Dr. Reddy’S Laboratories Limited A process for modifying high mannose and galactosylation content of a glycoprotein composition
PT3227454T (en) 2014-12-01 2020-04-06 Amgen Inc Process for manipulating the level of glycan content of a glycoprotein
EP3596225A1 (en) * 2017-03-14 2020-01-22 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
JP2021519068A (en) 2018-03-26 2021-08-10 アムジェン インコーポレイテッド Total non-fucosylated glycoform of antibodies produced in cell culture

Also Published As

Publication number Publication date
EP4034556A1 (en) 2022-08-03
US20220349898A1 (en) 2022-11-03
CN114450593A (en) 2022-05-06
MX2022003461A (en) 2022-04-19
AU2020355251A1 (en) 2022-04-21
CA3152547A1 (en) 2021-04-01
BR112022005583A2 (en) 2022-09-20
KR20220069982A (en) 2022-05-27
JP2022549329A (en) 2022-11-24
WO2021062372A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
IL292754A (en) Method of synthesis
ZA202102034B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
IL269651A (en) Improved method of producing collagenase
IL290825A (en) Methods of producing antibody compositions
GB201806072D0 (en) Methods of manufacture
IL286306A (en) Manufacturing methods for producing anti-tnf antibody compositions
IL284026A (en) Methods of producing heterodimeric antibodies
GB201804594D0 (en) Bonegraft substituteand method of manufacture
EP3893931A4 (en) Methods of using anti-trem2 antibodies
ZA202101837B (en) Method for the preparation of synthesis gas
GB201802839D0 (en) Method of manufacture
IL286307A (en) Methods for producing anti-tnf antibody compositions
IL285489A (en) Producing compositions comprising two or more antibodies
IL290324A (en) Compositions of trofinetide
IL288825A (en) Methods of producing an anti-α4β7 antibody
GB201805904D0 (en) Methods of Manufacture
EP3710482A4 (en) Compositions and methods for making and using bispecific antibodies
IL286309A (en) Methods for producing anti-tnf antibody compositions
IL283950A (en) Methods and compositions for producing cannabinoids
IL284086A (en) Controlled fucosylation of antibodies
GB201919385D0 (en) Compositions and methods of manufacture
GB201903055D0 (en) Method of oligonucleaotide synthesis
IL287756A (en) Methods of making antibodies
IL272058A (en) Stabilized antibody compositions and methods of producing same
GB201917499D0 (en) Methods of synthesis